GlassScriptPhysician profile
Dayna Vecchione
NPI 1265942536
$3,722.15
in general payments reported to CMS, 2019-2025
29 companies · $821 in 2025
The $821 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $1,244 · 2023: $311 · 2024: $426 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $958.80 | 2021-2024 | Relistor |
| Boston Scientific Corporation | $543.25 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16, General - Therapies |
| Abbvie INC. | $473.84 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $240.02 | 2021-2024 | |
| Nevro Corp. | $218.14 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $173.73 | 2021-2025 | Belbuca |
| Vertos Medical, INC. | $153.23 | 2022 | |
| Protega Pharmaceutials INC | $122.10 | 2025 | Roxybond |
| Relievant Medsystems, INC. | $116.84 | 2022 | |
| Abbott Laboratories | $103.92 | 2021-2025 | Eterna, Proclaim |
| Saluda Medical Americas, INC. | $99.30 | 2024-2025 | Evoke |
| Stimwave Technologies Incorporated | $65.39 | 2022 | |
| Globus Medical, INC. | $53.38 | 2025 | Senza |
| Amgen INC. | $42.54 | 2022 | |
| Atland Pharmaceuticals, LLC | $36.19 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $33.63 | 2022 | |
| Curonix LLC | $30.55 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biodelivery Sciences International, INC. | $30.51 | 2021 | |
| Nalu Medical, INC. | $26.02 | 2025 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $24.68 | 2025 | |
| Mdd US Operations, LLC | $23.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.26 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.79 | 2025 | Horizant |
| Averitas Pharma INC. | $21.83 | 2025 | Qutenza |
| Pfizer INC. | $21.75 | 2025 | |
| West Therapeutics Development, LLC | $20.66 | 2021 | |
| Medtronic, INC. | $15.96 | 2025 | Inceptiv |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2021 | |
| Allergan, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayna Vecchione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.